

**P&T Motion History
Hepatitis C – Direct-Acting Antivirals**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
daclastavir glecaprevir/pibrentasvir grazoprevir/elbasvir ledipasvir/sofosbuvir paritaprevir/ritonavir/ombitasvir paritaprevir/ritonavir/ombitasvir/ dasabuvir simeprevir sofosbuvir velpatasvir/sofosbuvir voxilaprevir/velpatasvir/sofosbuvir	<p>Hepatitis C – Genotype 1-6 After considering the evidence of safety, efficacy and special populations for the treatment of Hepatitis C, I move that</p> <p>daclastavir glecaprevir/pibrentasvir grazoprevir/elbasvir ledipasvir/sofosbuvir paritaprevir/ritonavir/ombitasvir paritaprevir/rit/ombitasvir/dasabuvir simeprevir sofosbuvir velpatasvir/sofosbuvir voxilaprevir/velpatasvir/sofosbuvir are safe and efficacious for their FDA approved indications. These drugs cannot be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Chew 2nd: Figueroa</p>	August 15, 2018	Yes Figueroa Chew	Yes Storhaug Sanderson	Passed unanimous